📊 FZMD Key Takeaways
Is Fuse Medical, Inc. (FZMD) a Good Investment?
Fuse Medical exhibits fundamental deterioration with negative stockholders' equity of -$231.6K, indicating the company is technically insolvent on a book value basis. Despite strong gross margins of 70%, the company is struggling with profitability (0.9% net margin) and revenue contraction (-8.7% YoY), while operating primarily on thin cash flow generation that may not be sustainable.
Fuse Medical shows some operational resilience with positive operating income, positive free cash flow, and a strong 70.0% gross margin, but those strengths are outweighed by weak scale, declining revenue, and extremely thin net profitability. Negative stockholders' equity, limited cash, weak quick liquidity, and low interest coverage point to a fragile balance sheet and reduce confidence in the quality and durability of earnings.
Why Buy Fuse Medical, Inc. Stock? FZMD Key Strengths
- Strong gross margin of 70% demonstrates pricing power and efficient production in medical supplies
- Positive operating cash flow of $231.7K with free cash flow matching OCF indicates no capital intensity
- Adequate liquid cash position of $253.4K provides near-term operational cushion
- High gross margin indicates favorable product economics and pricing structure
- Business remained modestly profitable with positive operating income and positive free cash flow
- Current ratio above 1.0 suggests near-term obligations are still being covered at a basic level
FZMD Stock Risks: Fuse Medical, Inc. Investment Risks
- Negative stockholders' equity of -$231.6K signals technical insolvency and erosion of shareholder value
- Revenue declining 8.7% YoY combined with minimal net margin of 0.9% suggests business model deterioration
- Critical liquidity weakness with quick ratio of 0.31x indicates difficulty meeting short-term obligations beyond cash on hand
- Liabilities exceed assets ($19.5M vs $19.3M), creating balance sheet stress despite current ratio appearing adequate
- Near-zero insider activity (0 Form 4 filings in 90 days) may indicate lack of management confidence
- Revenue declined 8.7% year over year, raising concern about demand stability and growth quality
- Negative stockholders' equity signals balance sheet weakness and limits financial flexibility
- Quick ratio of 0.31x and interest coverage of 1.8x leave little cushion if operations soften
Key Metrics to Watch
- Quarterly revenue trend and year-over-year growth trajectory
- Path to positive stockholders' equity and timeline for balance sheet recovery
- Operating margin expansion and net margin improvement
- Working capital and quick ratio trends to assess liquidity sustainability
- Revenue growth versus operating margin stability
- Cash balance and stockholders' equity trend
Fuse Medical, Inc. (FZMD) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The relatively thin 2.6% FCF margin may limit capital allocation flexibility.
FZMD Profit Margin, ROE & Profitability Analysis
FZMD vs Healthcare Sector: How Fuse Medical, Inc. Compares
How Fuse Medical, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Fuse Medical, Inc. Stock Overvalued? FZMD Valuation Analysis 2026
Based on fundamental analysis, Fuse Medical, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Fuse Medical, Inc. Balance Sheet: FZMD Debt, Cash & Liquidity
FZMD Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Fuse Medical, Inc.'s revenue has declined by 23% over the 5-year period, indicating business contraction. The most recent EPS of $-0.02 indicates the company is currently unprofitable.
FZMD Revenue Growth, EPS Growth & YoY Performance
FZMD Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2023 | $4.7M | $79.2K | $0.00 |
| Q1 2023 | $4.0M | -$228.4K | $0.00 |
| Q3 2022 | $4.3M | -$9.4K | $0.00 |
| Q2 2022 | $4.7M | -$85.5K | $0.00 |
| Q1 2022 | $4.4M | -$358.3K | N/A |
| Q3 2021 | $4.3M | $80.5K | $0.00 |
| Q2 2021 | $4.0M | -$85.5K | $0.00 |
| Q1 2021 | $4.4M | -$453.3K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Fuse Medical, Inc. Dividends, Buybacks & Capital Allocation
FZMD SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Fuse Medical, Inc. (CIK: 0000319016)
📋 Recent SEC Filings
❓ Frequently Asked Questions about FZMD
What is the AI rating for FZMD?
Fuse Medical, Inc. (FZMD) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (SELL) with 83% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are FZMD's key strengths?
Claude: Strong gross margin of 70% demonstrates pricing power and efficient production in medical supplies. Positive operating cash flow of $231.7K with free cash flow matching OCF indicates no capital intensity. ChatGPT: High gross margin indicates favorable product economics and pricing structure. Business remained modestly profitable with positive operating income and positive free cash flow.
What are the risks of investing in FZMD?
Claude: Negative stockholders' equity of -$231.6K signals technical insolvency and erosion of shareholder value. Revenue declining 8.7% YoY combined with minimal net margin of 0.9% suggests business model deterioration. ChatGPT: Revenue declined 8.7% year over year, raising concern about demand stability and growth quality. Negative stockholders' equity signals balance sheet weakness and limits financial flexibility.
What is FZMD's revenue and growth?
Fuse Medical, Inc. reported revenue of $9.0M.
Does FZMD pay dividends?
Fuse Medical, Inc. does not currently pay dividends.
Where can I find FZMD SEC filings?
Official SEC filings for Fuse Medical, Inc. (CIK: 0000319016) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is FZMD's EPS?
Fuse Medical, Inc. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is FZMD a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Fuse Medical, Inc. has a SELL rating with 83% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is FZMD stock overvalued or undervalued?
Valuation metrics for FZMD: ROE of N/A (sector avg: 15%), net margin of 0.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy FZMD stock in 2026?
Our dual AI analysis gives Fuse Medical, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is FZMD's free cash flow?
Fuse Medical, Inc.'s operating cash flow is $231.7K, with capital expenditures of $0.0. FCF margin is 2.6%.
How does FZMD compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 0.9% (avg: 12%), ROE N/A (avg: 15%), current ratio 1.06 (avg: 2).